



A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions by Industry



News highlights:

- Immusoft acquired Discovery Genomics Inc, based in Minneapolis, to gain its scientific expertise and key technology called the Sleeping Beauty Transposon System, which is a non-viral method of delivering genes into cells to prevent or alleviate a disease state.
- Juno outlined plans to leverage a Phase II study of JCAR015 for B cell acute lymphoblastic leukemia for an accelerated approval as early as 2017. Likewise, a Phase I study for JCAR017 in B cell non-Hodgkin lymphoma can be leveraged into a registration study that can start this year or next.
- Institute for Systems Biology is joining Providence Health & Services in a new affiliation. Specific research projects in the collaboration include efforts to spot the transition from wellness to common diseases early on, long-term analysis of Alzheimer’s risk, and new “systems-driven” treatment approaches to fatal brain tumors.
- Alder BioPharmaceuticals is planning to raise \$117 million in a stock offering. According to the company, underwriters J.P. Morgan Securities, Leerink Partners and Wells Fargo Securities have agreed to purchase ~5.4 million shares of common stock at \$21.855 per share. The public price will be \$23.25 per share.

Deal highlights:

- **Allen Institute for Brain Science** \$18.7M (Contract)
- **Act X** \$308,810 (Unknown)
- **Breast Microseed** \$100,000 (Debt)
- **Seattle Children’s Research Institute** \$1M (Grant)
- **University of Washington** \$250,000 (Grant)
- **Frazier Healthcare Partners** \$525M
- **The Paul G. Allen Frontiers Group** \$100M
- **2Morrow** \$325,000 (Debt)
- **Cyrus Biotechnology** \$535,000 (Debt)
- **Medstreaming** \$12.2M (Equity)
- **Prevencio** \$675,000 (Debt)
- **Silverback Therapeutics** \$10M (Equity)
- **Juno Therapeutics** \$50M (Partnership)


March total: \$649,708,810

2016 running total (Jan-Apr 18th): \$2,058,824,975

Life Science Transactions by Quarter: 2013 - 2015

At the end of Q1 2016, life science transactions totaled nearly \$2 billion, more than doubling first quarter transactions in 2015, and just \$350 million shy of the \$2.35 billion total in Q2 of 2015.

Transactions by Quarter (Millions)




Highlights from 1st quarter of 2016

- **Physio-Control** acquired by Stryker Corporation for \$1.28 billion.
- **The Paul G. Allen Frontiers Group** launched as the life sciences funding arm of the Allen Institute with \$100 million fund.
- **M3 Biotechnology** raised \$10 million (Equity). **Glycostasis** acquired by Eli Lilly and Company for an undisclosed amount.
- **Cytodyn** raised \$30.5 million (Equity).
- **Vicis** raised an \$8 million seed round.


*As of April 18, 2016

Young Companies (1-5 Years Old) Lead in Total Transactions (2013-2015)


Transactions by Industry and Age of Company



Transactions by Deal Size and Age of Company



Transactions by Deal Type and Age of Company



- Across the board, a few large deals account for the majority of transactions
- Early partnerships and venture capital funding for biopharma startups drive the majority of transactions in young companies (1-5 years old)
- Transactions for young medical technology startups are limited. However, more mature med tech companies (6-10 yrs and 11-15 yrs old) comprise 50% of deals
- As expected, companies between 11-15 yrs are responsible for the majority of IPOs and M&As

Washington-based Life Science Transactions 2016

Date	Company	Type	Amount
01/12/16	Blaze Bioscience	Debt	\$991,000
01/14/16	Stemgenics	Equity	\$930,000
01/20/16	Vicis	Seed	\$8,000,000
01/25/16	Clario Medical Imaging	Equity	\$185,000
02/02/16	ID Genomics	Equity	\$50,000
02/02/16	Oricula Therapeutics	Grant	\$2,060,000
02/11/16	M3 Biotechnology	Equity	\$10,000,000
02/16/16	KPI Therapeutics	Debt	\$50,500
02/16/16	Physio-Control	Acquisition	\$1,280,000,000
02/17/16	Glycostasis	Acquisition	undisclosed
02/23/16	Cytodyn	Equity	\$30,574,665
02/24/16	Ave Maria Biotechnology	Equity	\$40,000
02/29/16	VitalWare	Series A	undisclosed
03/03/16	LabConnect	Venture Equity	\$4,000,000
03/11/16	Allen Institute for Brain Science	Contract	\$18,700,000
03/16/16	Ave Maria Biotechnology	Equity	\$350,000
03/17/16	Act X	Unknown	\$308,810
03/22/16	Seattle Children's Research Institute	Grant	\$1,000,000
03/22/16	Breast Microseed	Debt	\$100,000
03/23/16	Frazier Healthcare Partners	Fund	\$525,000,000
03/23/16	University of Washington	Grant	\$250,000
03/24/16	The Paul G. Allen Frontiers Group	Fund	\$100,000,000
04/06/16	Cyrus Biotechnology	Debt	\$535,000
04/06/16	2Morrow	Debt	\$325,000
04/07/16	Medstreaming LLC	Equity	\$12,200,000
04/07/16	Prevencio, Inc	Debt	\$675,000
04/08/16	Medstreaming LLC	Equity	\$2,500,000
04/12/16	Silverback Therapeutics	Equity	\$10,000,000
04/18/16	Juno Therapeutics	Partnership	\$50,000,000
2016 Running Total as of April 18, 2016			\$2,058,824,975

Attend [Life Science Innovation Northwest \(LSINW\)](#) on June 1-2, 2016

LSINW connects **world-class industry leaders** and showcases the Pacific Northwest as a **global center for life science advancement**.

Want to Showcase Your Organization to Attendees? Here are Four Opportunities to Participate at LSINW:

- [LSINW Venture Investment & Partnering \(VIP\) Forums](#)**: New this year! Apply for the opportunity to meet 1:1 with [GSK](#), [Broadview Ventures](#), [Telegraph Hill Partners](#), and [HealthQuest Capital](#) to discuss future business collaborations and partnerships.
Apply at: <http://www.lifesciencewa.org/?page=VIPForumApp> by May 6!
- [Present A Poster](#)**: The Poster Session is aimed at helping very early stage companies obtain insights from and network with savvy investors and biotech executives.
Apply at: <https://www.surveymonkey.com/r/2016posterlsinw> by April 29!
- [Present on Podium](#)**: Podium Presentations are ideal for life science organizations seeking to connect with industry business development executives, investors, entrepreneurs and other strategic partners.
Apply at: https://www.surveymonkey.com/r/LSINW_Podium16 by April 29!
- [Become a LSINW Sponsor](#)**: Raise your organization's profile at the largest gathering of Life Science industry members in North America!



Washington-based Life Science Transactions 2015

Date	Company	Type	Amount	Date	Company	Type	Amount
01/22/15	Alder Biopharmaceuticals	Second public offering	\$203,600,000	06/29/15	Nexgenia	Equity	\$1,617,582
01/22/15	Adaptive Biotechnologies	Series E	\$93,750,000	06/30/15	Vera Whole Health, Inc	Debt	\$2,000,000
01/28/15	Vesiflo	Convertible note	\$650,000	07/13/15	Arivale	Series B	\$36,000,000
01/30/15	MalarVx, Inc	Equity	\$110,000	07/14/15	Cytodyn	Equity	\$1,972,500
02/05/15	Alpine Immune Sciences	Seed	\$1,300,000	07/14/15	RF Surgical Systems	Acquisition	\$235,000,000
02/05/15	M3 Biotechnology	Equity	\$150,000	07/21/15	Deep Domain	Equity	\$260,507
02/10/15	Valant Medical Solutions	Venture Equity	\$285,350	07/31/15	Qliance Medical Management	Debt	\$2,676,730
02/13/15	Stasys Medical	Series A	\$160,000	08/07/15	Precision Image Analysis	Equity	\$60,348
02/18/15	StratoScientific	Venture Equity	\$550,000	08/11/15	Vicis	Venture Equity	\$1,500,000
02/23/15	Dendreon	Acquisition	\$495,000,000	08/12/15	Marina Biotech	Equity	\$1,100,000
03/06/15	Cerevast Therapeutics	Series C	\$1,375,000	08/13/15	Bloomingtondale Memory Care	Equity	\$3,373,525
03/09/15	KinDex Pharmaceuticals	Series A	\$500,000	08/17/15	OtoNexus Medical Technologies	Debt	\$754,990
03/11/15	Cardiac Dimensions	Venture Equity	\$15,200,000	08/18/15	Immusoft	Debt	\$375,000
03/15/15	Medical Mirror Systems	Equity	\$250,000	08/19/15	Sound Pharmaceuticals	Debt	\$300,000
03/19/15	Nortis	Venture Equity	\$408,845	08/21/15	Navigating Cancer	Venture Equity	\$6,605,573
03/20/15	Healthentic	Series C	\$3,750,000	08/28/15	Aqueduct Critical Care	Equity	\$3,712,304
03/20/15	StratoScientific	Venture Equity	\$150,000	09/02/15	Kona Medical	Debt	\$10,000,300
03/25/15	Cadence Biomedical	Equity	\$959,578	09/14/15	Seattle Genetics	Second public offering	\$525,000,000
04/08/15	NuvoMed	Equity	\$390,637	09/14/15	Impel Neuropharma	Equity	\$1,257,927
04/10/15	Cardeas Pharma	Series B	\$3,500,000	09/18/15	Impel Neuropharma	Equity	\$4,000,000
04/13/15	Carena	Debt	\$500,000	09/21/15	Cardiac Insight	Undisclosed	\$3,500,000
04/17/15	X2 Biosystems	Venture Equity	\$350,000	09/22/15	Just Biotherapeutics	Series A	\$15,000,000
04/23/15	Deep Domain	Venture Equity	\$30,000	09/24/15	VDA Pharma	Debt	\$55,000
04/24/15	Mpirica Health	Series A	\$1,600,000	09/24/15	Joylux	Seed	\$3,000,000
05/01/15	Mirabilis Medica	Debt	\$2,920,000	09/30/15	Accelerator Corporation	Venture Equity	\$11,700,000
05/06/15	Adaptive Biotechnologies	Series F	\$195,000,000	10/02/15	Spiral Genetics	Debt	\$200,000
05/06/15	Theraclone Sciences	Venture Equity	\$3,080,000	10/04/15	Cytodyn	Equity	\$2,693,800
05/06/15	Cyrus Biotechnology	Debt	\$850,000	10/15/15	Global Health Vaccine Center of Innovation	Partnership	\$9,500,000
05/06/15	InDemand Interpreting	Venture Equity	\$4,000,000	10/19/15	Novuson Surgical	Equity	\$500,000
05/14/15	Cytodyn	Debt	\$3,281,050	10/27/15	Alpine Immune Sciences	Partnership	\$5,000,000
05/18/15	Tissue Regeneration Systems	Debt	\$2,093,182	10/27/15	Park Boulevard Memory Care, LLC	Equity	\$3,524,925
05/19/15	KPI Therapeutics	Equity	\$27,000	10/30/15	Metheor Therapeutics	Equity	\$90,000
05/21/15	Ventec Life Systems	Venture Equity	\$8,192,480	11/04/15	Clarity Health	Acquisition	Undisclosed
05/27/15	BioViva USA	Equity	\$250,000	11/11/15	Aminex Therapeutics	Series A	\$4,000,000
06/02/15	C-SATS	Venture Equity	\$2,500,000	11/11/15	Mpirica Health	Venture Equity	\$400,000
06/03/15	Magnolia Medical Technologies	Venture Equity	\$6,235,322	11/13/15	Qliance Medical Management	Equity	\$450,000
06/04/15	Carena	Series B	\$13,300,000	11/16/15	Implicit Bioscience	Equity	\$50,800
06/05/15	Valant Medical Solutions	Venture Equity	\$3,000,000	11/20/15	M3 Biotechnology	Equity	\$3,500,000
06/11/15	Glycostasis	Equity	\$149,998	11/25/15	OtoNexus Medical Technologies	Debt	\$1,403,080
06/16/15	Altius Institute for Biomedical Sciences	Partnership	\$95,000,000	12/01/15	Universal Cells	Partnership	\$5,500,000
06/16/15	Remote Medical International	Partnership	\$95,000,000	12/01/15	EndoGastric Solutions	Equity	\$50,000,000
06/17/15	Stratos Genomics	Series B	\$19,999,976	12/04/15	Breast Microseed	Debt	\$500,000
06/20/15	Global Innovation Exchange	Partnership	\$45,000,000	12/16/15	Matrix Genetics	Debt	\$1,600,000
06/20/15	Vicis	Seed	\$1,600,000	12/23/15	Switch Healthcare	Equity	\$300,000
06/22/15	Qliance Medical Management	Debt	\$520,753	12/24/15	Nohla Therapeutics	Equity	\$21,000,000
06/24/15	Nativis	Venture Equity	\$725,000	12/24/15	Nativis	Equity	\$250,000
06/24/15	Cadence Biomedical	Series B	\$1,200,000	12/29/15	PhaseRx	Debt	\$4,000,000
06/25/15	Blaze Bioscience	Equity	\$85,400				
06/28/15	Juno Therapeutics	Partnership	\$1,000,000,000				
2015 Total							\$3,313,814,462

Check out the past issues of the Washington Life Science Report at:

<http://www.lifesciencewa.org/?page=WAINvestment>